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Mutations in rhodopsin can cause misfolding and aggregation of the receptor, which leads to retini-
tis pigmentosa, a progressive retinal degenerative disease. The structure adopted by misfolded opsin
mutants and the associated cell toxicity is poorly understood. Förster resonance energy transfer
(FRET) and Fourier transform infrared (FTIR) microspectroscopy were utilized to probe within cells
the structures formed by G188R and P23H opsins, which are misfolding mutants that cause autoso-
mal dominant retinitis pigmentosa. Both mutants formed aggregates in the endoplasmic reticulum
and exhibited altered secondary structure with elevated b-sheet and reduced a-helical content. The
newly formed b-sheet structure may facilitate the aggregation of misfolded opsin mutants. The
effects observed for the mutants were unrelated to retention of opsin molecules in the endoplasmic
reticulum itself.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Retinitis pigmentosa (RP) is a hereditary and progressive retinal
degenerative disease that can be caused by defects in different
genes [1,2]. Mutations in the gene for rhodopsin, the light receptor
in rod photoreceptor cells that initiates vision via phototransduc-
tion, are the largest genetic cause of autosomal dominant RP [1].
Over 100 mutations in rhodopsin have been detected in patients
with RP [2,3]. A majority of these mutations cause misfolding of
the apoprotein opsin, a membrane protein with 7 a-helical trans-
membrane domains, and an inability to bind the chromophore11-cis retinal [4,5]. Misfolded opsin mutants are improperly tar-
geted in the cell and retained in the endoplasmic reticulum (ER)
forming aggregates [6,7]. Thus, RP can be classified as a protein
conformational or protein misfolding disease.
Misfolded opsin mutants that cause RP are often presumed to
form amorphous aggregates [8], which can cause ER stress leading
to cell death. A large number of conformational diseases are caused
by toxic amyloid-type aggregates [9,10]. Thus far, only amyloid-
type aggregates formed by peptides or globular proteins have been
detected and studied. It is unclear whether or not membrane pro-
teins like opsin can also form aggregates that share features dis-
played by amyloids. While aggregation underlies the toxicity of
misfolded opsin mutants [6,11], the structures adopted by mis-
folded opsins and the resulting aggregates are unknown. The lim-
ited structural information about misfolded opsin mutants have
been inferred from receptors extracted from the cell using deter-
gent [12]. Structural insights on misfolded opsin mutants within
the context of the cell are absent.
The structural characterization of membrane proteins presents
a challenge since they require a lipid bilayer for stabilization and
function. Conventional approaches are often not amenable for
examining the structure of membrane proteins under physiologi-
cally relevant conditions. In contrast, Förster resonance energy
transfer (FRET) and Fourier transform infrared (FTIR) microspec-
troscopy can provide structural information about membrane pro-
teins within the native context of the cell [13,14]. Thus, FRET and
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tigate the structural changes accompanying misfolded mutants of
opsin within the cell.
2. Materials and methods
2.1. DNA constructs
SCFP3A and mTurquoise (mTq) are variants of cyan fluorescent
protein (CFP) and SYFP2 is a variant of yellow fluorescent protein
(YFP). The vectors pSCFP3A-N1, pSYFP2-N1, and pmTq-C1 were
generated as described previously [14,15]. The sequence 50-ACGGA
GACCAGCCAGGTGGCTCCAGCCTAA-30, which corresponds to a 1D4
epitope (TETSQVAPA) [16], was added to the end of the sequences
for SCFP3A or SYFP2 by PCR amplification using pSCFP3A-N1 and
pSYFP2-N1 as templates, generating the products SCFP3A-1D4
and SYFP2-1D4, respectively. The sequences for the fluorescent
proteins in pSCFP3A-N1 and pSYFP2-N1 were replaced with the
PCR amplified SCFP3A-1D4 and SYFP2-1D4 to generate the vectors
pSCFP3A-1D4-N1 and pSYFP2-1D4-N1, respectively. The cDNA for
murine rhodopsin (mRho) was amplified by PCR to include an
EcoRI restriction endonuclease site and Kozak sequence at the 50
end and a BamHI restriction endonuclease site at the 30 end of
the sequence with the stop codon removed. This amplified mRho
sequence was inserted into pSCFP3A-1D4-N1 and pSYFP2-1D4-
N1 at the EcoRI and BamHI restriction endonuclease sites to gener-
ate the vectors pmRho-SCFP3A-1D4 and pmRho-SYFP2-1D4. To
generate vectors for tagged rhodopsin containing an ER retention
sequence, the sequence 50-ACTTTAGCTTCTTCTTTAACTTTCAAGAAG
TATCTTTAA-30, which contains a KKYL ER retention sequence [17],
was added to the end of the sequences for mTq or SYFP2 by PCR
using vectors containing sequences for these fluorescent proteins
as the template. SYFP2-1D4 in pmRho-SYFP-1D4 was replaced by
either the PCR products mTq-KKYL or SYFP2-KKYL to generate
the vectors pmRho-mTq-KKYL and pmRho-SYFP2-KKYL. To gener-
ate a vector for the expression of untagged rhodopsin, the cDNA for
mRho was amplified by PCR to include an EcoRI restriction
endonuclease site and Kozak sequence at the 50 end and a NotI
restriction endonuclease site at the 30 end. This amplified PCR pro-
duct was inserted into pSCFP3A-N1 at the EcoRI and NotI restric-
tion endonuclease sites, which replaced the sequence for the
fluorescence protein with the mRho sequence to generate the vec-
tor pmRho. The P23H and G188R mutations were introduced
adapting procedures in the QuickChange II Site-Directed Mutagen-
esis Kit (Agilent Technologies, Santa Clara, CA). The following
primers were used: P23H-forward, 50-GTGCGGAGCCACTTCGAG
CAG-30; P23H-reverse, 50-CTGCTCGAAGTGGCTCCGCCAC-30;
G188R-forward, 50-TGTTCATGCAGGATTGACTAC-30; G188R-
reverse, 50-GTAGTCAATCCTGCATGAACA-30. The vectors generated
were used for transient transfection of HEK293 cells.
2.2. Transient transfection of HEK293 cells
HEK293T/17 cells (American Type Culture Collection, Manassas,
VA) were grown in Dulbecco’s Modified Eagle’s Medium (DMEM)-
high glucose (Thermo Fisher Scientific, Waltham, MA), supple-
mented with 10% fetal bovine serum (Thermo Fisher Scientific,
Waltham, MA). Prior to transfection, HEK 293T/17 cells were
seeded in a 12 well plate at a density of 1.5  105 cells per well.
Cells used for confocal imaging were seeded on poly-L-lysine trea-
ted #1.5 coverslip glass (Thermo Fisher Scientific, Waltham, MA).
Cells used for FTIR were seeded on 13  1 mm CaF2 discs (Crystran
Limited, Poole, United Kingdom). Cells were incubated in a 5% CO2
incubator for 24 h, after which cells reached 60% confluency. Trans-
fection of cells with DNA vectors described earlier was performedusing Lipofectamine 2000 (Invitrogen, Carlsbad, CA). 200 ng of a
single DNA vector or 200 ng each of two DNA vectors were used
in transfections and cotransfections, respectively. For studies
requiring visualization of the ER, cells were cotransfected with
1000 ng of the vector pDsRed2-ER (Clontech, Mountain Valley,
CA), which codes for an ER marker. 24 h post-transfection, the
media was removed and each well was washed once with 1 mL
PBS (4.3 mM Na2HPO47H2O, 1.4 mM KH2PO4, 137 mM NaCl,
2.7 mM KCl, pH 7.3). For FRET assays, cells were resuspended in
3 mL of PBS.
2.3. Confocal microscopy
Cells on coverslips were fixed in 4% paraformaldehyde for
10 min at room temperature. Cells were washed with PBS three
times. The plasma membrane was stained by wheat germ agglu-
tinin (WGA)-Alexa Fluor 647 conjugate (Invitrogen, Carlsbad, CA)
at a 1:200 dilution for 10 min at room temperature. Cells were
washed three times with PBS. Cell nuclei were stained with
0.5 lg/mL of DAPI for 10 min at room temperature. Cells were
washed twice with PBS and once with water. Coverslips were
mounted on a glass slide using ProLong Gold Antifade Mountant
(Life Technologies, Eugene, OR). Confocal microscopy was per-
formed on a SP8 confocal microscope (Leica, Buffalo Grove, IL)
equipped with a 100/1.4-NA oil objective. DAPI was detected by
exciting samples with a 405 nm diode laser and collecting the
emission signal at 415–430 nm. YFP was detected by exciting sam-
ples at 514 nm using a tunable white light laser and collecting the
emission signal at 520–560 nm. WGA-Alexa Fluor 647 was
detected by exciting samples at 650 nm using a tunable white light
laser and collecting the emission signal at 660–680 nm. DsRed2-ER
was detected by exciting samples at 558 nm using a tunable white
laser and collecting the emission signal at 570–600 nm.
2.4. FRET assay
FRET assays on cell suspensions were conducted on a
FluoroMax-4 spectrofluorometer (Horiba Jobin Yvon, Edison, NJ).
Samples were excited at 425 nm with a 5 nm excitation slit width
to excite CFP. The emission spectra were obtained with a 10 nm
emission slit width. All samples were maintained at 25 C with a
circulating water bath. The samples were then treated 5 min with
1.3 mM n-dodecyl-b-D-maltoside (DM, Anatrace, Maumee, OH) and
5 min with 3.3 mM SDS (Invitrogen, Carlsbad, CA). Fluorescence
spectra were obtained after each detergent treatment step. Back-
ground was computed using negative control cells coexpressing
untagged opsin and YFP-tagged opsin.
2.5. FTIR microspectroscopy
FTIR microspectroscopy was performed using a Thermo Nicolet
Continuum IR microscope coupled to beamline U2B at the National
Synchrotron Light Source (NSLS) at Brookhaven National Laboratory
(Upton, NY). Additional spectra were collected at beamline 1.4.4 at
the Advanced Light Source (ALS) at Lawrence Berkeley National Lab-
oratory (Berkeley, CA). In both cases, a 32 IR Schwarzchild objec-
tive produced a 10  10 lm beam. A 4 cm1 spectral resolution
and 128 scans per spectrum were used over the mid-infrared region
(4000–800 cm1). For each transfected cell type, spectra were col-
lected from regions of 40–50 cells that exhibited bright fluorescence
from YFP. For transfected cells using constructs without YFP, spectra
were collected from all areas of the cell and were manually sorted.
Thus, spectra of untagged opsins are not as reliable as those from
tagged opsins since the absence of fluorescence from YFP prevented
an accurate localization of the opsins in the cell. Spectra were also
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resent the averages of the 40–50 spectra. For each average spectrum,
the b-sheet/amide I ratio and the a-helix/amide I ratio were calcu-
lated by integrating the b-sheet component (1625–1630 cm1) or
a-helix component (1650–1655 cm1) and ratioing to the amide I
band area (1600–1700 cm1) using a linear baseline from 1480 to
1800 cm1. The integrated values for the b-sheet component and
a-helix component were also used to compute the b-sheet/a-helix
ratio.
2.6. Generation of stable HEK293 cell lines
Stable HEK293 cell lines expressing mRho, mRho-SCFP3A-1D4, or
mRho-SYFP2-1D4 were generated using the Flp-In System (Invitro-
gen, Carlsbad, CA). The cDNA for mRho, mRho-SCFP3A-1D4, and
mRho-SYFP2-1D4 were subcloned from the vectors pmRho,
pmRho-SCFP3A-1D4, and pmRho-SYFP2-1D4 into the vector
pcDNA5/FRT at the NheI and NotI restriction endonuclease sites.
2.7. Reconstitution and purification of isorhodopsin
Stable HEK293 cell lines expressing mRho, mRho-SCFP3A-1D4,
or mRho-SYFP2-1D4 were grown in DMEM-high glucose supple-
mented with 10% fetal bovine serum on 100  20 mm tissue cul-
ture plates. For each purified preparation, cells were grown to
confluency, harvested from 10 to 30 plates, and resuspended in
4 mL of PBS supplemented with a protease inhibitor cocktail tablet
(Roche Diagnostics, Indianapolis, IN). All reconstitution and purifi-
cation procedures were performed in the dark or under dim red
light conditions. Opsin expressed in the stable HEK293 cells was
reconstituted with 9-cis retinal (Sigma–Aldrich, St. Louis, MO). A
stock solution of 9-cis retinal in DMSO (100 mM) was added to
the cell suspension to achieve a final concentration of 100 lM.
The cell suspension with chromophore was shaken at room tem-
perature for 2 h. Reconstituted cells were pelleted by centrifuga-
tion at 90000g for 10 min at 4 C. The cell pellet was
resuspended and homogenized in 10 mM Bis-Tris propane,
500 mM NaCl, 20 mM DM, pH 7.5 supplemented with a protease
inhibitor cocktail tablet. The cell suspension was shaken at room
temperature for 15 min and then centrifuged at 90000g for
20 min at 4 C. The supernatant was loaded on a 6  30 mm col-
umn packed with Sepharose 4B (Santa Cruz Biotechnology, Santa
Cruz, CA) coupled to anti-1D4 antibody [16]. Isorhodopsin was
purified as described previously [18].
2.8. UV–visible absorbance spectroscopy
Absorbance spectra of purified isorhodopsin were obtained
using a Lambda 35 UV–visible spectrophotometer (PerkinElmer,
Waltham, MA). Hydroxylamine hydrochloride was added from a
1 M (pH 7.0) stock solution to purified samples to achieve a final
concentration of 20 mM. A first absorbance spectrumwas obtained
using buffer as a blank. A difference spectrum was then obtained
by using the unbleached sample as the blank, bleaching the sample
for 5 min using a MI-150 Fiber-Lite illuminator (Dolan-Jenner
Industries, Boxborough, MA) equipped with a 480–520 nm band-
pass filter, and then reading the bleached sample.
2.9. Metarhodopsin (MII) decay assay
Purified isorhodopsin was investigated in 20 mM Bis-Tris pro-
pane, 120 mM NaCl, 2 mM DM, pH 6.0. Samples were bleached
for 15 s using a MI-150 Fiber-Lite illuminator equipped with a
480–520 nm band-pass filter. Intrinsic tryptophan fluorescence
was then measured over time on a FluroMax-4 spectrofluorometer
by using an excitation wavelength of 295 nm (1 nm slit width) andemission wavelength of 330 nm (10 nm slit width). A circulating
water bath was used to maintain a constant sample temperature
of 20 C. The increase in tryptophan fluorescence correlates with
the release of all-trans-retinal from the binding pocket of rhodop-
sin occurring upon the decay of the active MII state [19]. Fluores-
cence data were analyzed by non-linear regression fitting to an
exponential one-phase decay equation in Prism 6 (GraphPad Soft-
ware, La Jolla, CA). Two different preparations were tested for puri-
fied untagged, CFP-tagged, and YFP-tagged isorhodopsin.3. Results and discussion
3.1. Characterization of tagged opsins expressed in HEK293 cells
The opsin mutants investigated in the current study contain the
G188R and P23H mutations. The P23H mutation in opsin was the
first one discovered to cause autosomal dominant RP in patients
and is the most common RP-causing mutation in opsin in the Uni-
ted States [20]. The G188R mutation in opsin also causes autoso-
mal dominant RP [21]. Both point mutations cause misfolding of
opsin [12,22]. Wild-type (WT), G188R, and P23H opsins were
expressed in HEK293 cells. Expression of mutant opsins in cultured
cells such as HEK293 or COS-1 cells has served as a good model
system to examine protein misfolding and preciliary targeting
events [23]. Opsins were tagged at the C-terminus with variants
of the fluorescent proteins cyan fluorescent protein (CFP) or yellow
fluorescent protein (YFP) for visualization of the receptors in the
cell and for FRET studies [24].
To test whether or not tagging opsin with fluorescent proteins
impacts protein folding or function, the ability to bind chro-
mophore and receptor activation were investigated. Only properly
folded opsin can covalently bind the chromophore 11-cis retinal to
form rhodopsin. To determine the ability of tagged WT opsin to
bind chromophore, the apoprotein was reconstituted with a more
stable isomer of 11-cis retinal, 9 cis-retinal. The binding of 9 cis-
retinal to opsin forms isorhodopsin, which is functionally similar
to rhodopsin except for a blue-shifted absorbance maximum of
487 nm [25]. Purified untagged opsin expressed in HEK293 cells
and reconstituted with 9-cis retinal exhibited the characteristic
absorbance maximum for isorhodopsin at 487 nm (Fig. 1A). Puri-
fied opsins tagged with either CFP or YFP displayed complex absor-
bance spectra due to contributions from both isorhodopsin and the
fluorescent proteins (Fig. 1B and C). To separate out the component
corresponding to isorhodopsin, difference spectra were recorded
after bleaching samples. The difference spectra displayed minima
at 487 nm, thereby indicating that both CFP- and YFP-tagged
opsins bind 9-cis retinal.
Activation of rhodopsin or isorhodopsin occurs after the light-
induced isomerization of 11-cis retinal or 9-cis retinal to all-trans
retinal [26]. This isomerization of bound chromophore is evident
in the difference absorbance spectra collected after bleaching sam-
ples. The disappearance of absorbance derived from 9-cis retinal at
487 nm is accompanied by the appearance of absorbance derived
from all-trans retinal at 368 nm (Fig. 1A–C). The active state of rho-
dopsin or isorhodopsin, referred to as metarhodopsin II (MII),
decays by releasing all-trans retinal from the binding pocket in
opsin. The MII decay rate was determined for untagged and tagged
isorhodopsin by monitoring the dequenching of a tryptophan resi-
due that correlates with the release of all-trans retinal from the
binding pocket in opsin of the MII state [19]. The MII state of
untagged isorhodopsin decayed with a time constant of 22 min
(Fig. 1D). The MII states of CFP- and YFP-tagged isorhodopsin dis-
played similar decay rates that were about 1.3-fold slower than
that observed for untagged isorhodopsin (Fig. 1E and F). In previ-
ous studies, fluorescent proteins were shown not to impact the
Fig. 1. (A)–(C) UV/vis absorbance spectroscopy conducted on purified untagged (A), CFP-tagged (B), or YFP-tagged (C) opsin reconstituted with 9-cis retinal. Absorbance
spectra were obtained for unbleached samples using the buffer as the blank (solid line) and bleached samples using the unbleached sample as the blank (dotted line). (D)–(F)
MII decay of untagged (D), CFP-tagged (E), or YFP-tagged (F) isorhodopsin determined by dequenching of tryptophan fluorescence. Curves were fit by non-linear regression
assuming first-order reaction kinetics to determine the time constant (s). The mean values for time constants are shown with the standard deviation and number of
experiments (n).
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lated by rhodopsin kinase [27]. Taken together, receptor tagged
with either CFP or YFP are functional, although the additional mass
of the attached fluorescent protein slows down the rate of MII
decay somewhat.
The localization of tagged WT, G188R, and P23H opsins in
transfected HEK293 cells was investigated by confocal micro-
scopy. Wheat germ agglutinin (WGA) was used to stain the
plasma membrane (Fig. 2A–C) and an ER marker was coexpressedA B 
E F 
I J 
WT G188R 
Fig. 2. (A)–(H) Confocal microscopy of HEK293 cells expressing YFP-tagged opsins (gre
retention sequence (WT-KKYL) (D) and (H). Cells were stained either with the plasma m
shown in red. DAPI staining is shown in blue. Scale bar, 10 lm. (I)–(L) FRET between coex
suspensions were excited at 425 nm. Emission spectra from untreated (blue), DM treate
emission peak at 527 nm and dequenching of the CFP emission peak at 474 nm upon dto determine ER localization (Fig. 2E–G). As shown previously
[4,6,7], WT opsin was properly targeted to the plasma membrane
and largely excluded from the ER whereas the G188R and P23H
mutants were mislocalized and retained in the ER (Fig. 2). The
retention of mutant receptors in the ER of HEK293 cells recapit-
ulates the effects observed in photoreceptor cells of the retina
[28–30], although a larger fraction of the misfolded receptor is
rapidly degraded in photoreceptor cells compared to that in cul-
tured cells [31].C 
G H 
K L 
P23H WT-KKYL 
D 
en): WT (A) and (E), G188R (B) and (F), P23H (C) and (G), or WT opsin with an ER
embrane marker WGA (A)–(D) or with the ER marker DsRed2-ER (E)–(H), which is
pressed CFP- and YFP-tagged WT (I), G188R (J), P23H (K), or WT-KKYL (L) opsin. Cell
d (red), and SDS treated (green) cells are shown. FRET is evident by the sensitized
etergent treatment.
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HEK293 cells
Natively, rhodopsin and opsin in photoreceptor cells form oligo-
mers organized into nanodomains that can be disrupted by the
mild detergent n-dodecyl-b-D-maltoside (DM) [32–35]. Oligomers
of tagged rhodopsin and opsin have also been detected in COS-1
and HEK293 cells and liposomes by FRET approaches [6,36–38].
Similar to native conditions, oligomers of rhodopsin in heterolo-
gous expression systems are disrupted by DM [38]. Consistent with
these previous studies, CFP- and YFP-tagged WT opsin co-
expressed in HEK293 cells exhibited FRET that could be disrupted
by treatment with DM (Fig. 2I). FRET has also been used previously
to investigate the interactions between P23H opsins in HEK293
cells [6]; however, monitoring the FRET signal alone cannot differ-
entiate between oligomers normally formed by WT opsin versus
non-native oligomers (i.e., aggregates) formed by misfolded opsins.
Coexpression of CFP- and YFP-tagged misfolded opsin mutants in
HEK293 cells exhibited FRET; however, the FRET signal could not
be completely eliminated by treatment with DM (Fig. 2J and K).
The stronger detergent SDS was required to fully disrupt the FRET
signal. Thus, the sensitivity of the FRET signal to DM treatment
allows for the differentiation between misfolded mutant aggre-
gates and normal opsin oligomers.
To determine whether or not retention in the ER itself promotes
aggregation of opsin, YFP-tagged WT opsin with an ER retention
sequence (WT-KKYL) was expressed in HEK293 cells and investi-
gated [17]. Similar to the mutant opsins, tagged WT-KKYL opsin
was localized in the ER and excluded from the plasma membrane
(Fig. 2D and H). FRET studies were conducted to determine if
WT-KKYL opsin forms oligomers or aggregates. FRET was observed
in cells coexpressing CFP- and YFP-tagged WT-KKYL opsin, which
was disrupted by treatment with DM (Fig. 2L). FRET results of
WT-KKYL opsin are more similar to those of WT opsin than to
those of the mutant opsins. Thus, the retention of WT opsin in
the ER does not promote aggregation.
3.3. Secondary structure changes in misfolded opsin mutants
The nature of the structure adopted by misfolded opsin mutants
in HEK293 cells was investigated by synchrotron FTIR microspec-
troscopy. FTIR spectroscopy is a widely used technique for determin-
ing the secondary structure of proteins and synchrotron-based FTIR
microspectroscopy enables the localization of these structures
within a cell at subcellular resolution and with a high signal-to-
noise ratio [13,39]. In this study, FTIR spectra were obtained from
cells grown on CaF2 discs. Spectra were collected from regions in
the cell exhibiting bright fluorescence from YFP (e.g., Fig. 3A).
In all cells, the two most prominent peaks in the FTIR spectra
were the amide I (1650 cm1) and amide II (1550 cm1) protein
bands (Figs. S1–S3). The amide I band contains much of the sec-
ondary structure information about proteins [39]. a-Helices and
b-sheets exhibit absorbance in the spectra at 1655 cm1 and
1630 cm1, respectively. Transforming the absorbance spectra into
second derivative spectra provides more detailed and resolved
spectra [39]. Results showed a difference in the amide I band of
FTIR spectra collected from untransfected cells and cells expressing
YFP-tagged WT opsin, which included an increase in absorbance at
1630 cm1 for cells expressing tagged WT opsin (Fig. 3D). The sec-
ond derivative spectrum displayed a clear change in absorbance at
1630 cm1 for cells expressing tagged WT opsin (Fig. 3C), which
was indicative of an increase in b-sheet structure. A similar change
was also observed in this region of the spectrum in cells expressing
YFP alone. Since YFP has a b-barrel structure, the increase in absor-
bance at 1630 cm1 observed in cells expressing tagged WT opsin
likely derives from the b-sheet structure of the attached YFP ratherthan the structure of opsin. Consistent with this prediction, the
FTIR spectrum for untagged WT opsin was similar to that of
untransfected HEK293 cells at 1630 cm1.
Cells expressing YFP-tagged forms of either the G188R or P23H
mutants displayed an even greater increase in absorbance at
1630 cm1 compared to cells expressing YFP-tagged WT opsin
(Fig. 3E and F). This increased absorbance for the mutants points
to changes in the secondary structure of the opsin molecule itself.
This was confirmed by examining cells expressing untagged opsin
mutants, which also displayed an increase in absorbance at
1630 cm1 (Fig. 3G and H). Furthermore, when mapping the
b-sheet content in the HEK293 cells, regions with elevated
b-sheet content were clearly co-localized with the bright YFP fluo-
rescence signal from tagged misfolded opsins (Fig. 3A and B). Ele-
vated b-sheet content was not observed in maps of HEK293 cells
expressing tagged WT opsin. Retention of opsin in the ER itself
did not result in elevated b-sheet content as the FTIR spectrum
for YFP-tagged WT-KKYL opsin was similar as that for tagged WT
opsin at 1630 cm1 (Fig. 3E and F).
The change in secondary structure of the misfolded mutants was
quantified by calculating the b-sheet/a-helix ratio from FTIR spectra
and comparing this value with that computed from the WT opsin
spectrum. A 14% and 24% increase in b-sheet content relative to a-
helical content was observed in spectra for the G188R and P23H
mutants, respectively. This increase resulted from both an increase
in b-sheet structure and decrease in a-helical structure in cells
expressing the mutants compared to those expressing WT opsin. A
7% increase in b-sheet structure and 6% decrease in a-helical struc-
ture were observed for G188R opsin and a 14% increase in b-sheet
structure and 8% decrease in a-helical structure were observed for
P23H opsin. In contrast, no change in a-helical and b-sheet structure
was detected for tagged WT-KKYL. Thus, a conversion of a-helical
structure to b-sheet structure appears to occur in the mutant opsins
that are unrelated to the retention of opsin molecules in the ER.
The changes in secondary structure of misfolded opsins
detected in transfected HEK293 cells are consistent with previous
in vitro studies on purified receptors. A decrease in a-helical struc-
ture and increase in b-sheet structure has been observed previ-
ously by infrared reflection absorption spectroscopy in purified
rhodopsin induced to unfold by environmental perturbation [40].
Thus, misfolding of opsin promoted by mutation or environmental
perturbations may result in similar secondary structure changes. A
change in secondary structure has also been observed previously
by circular dichroism (CD) spectroscopy on detergent-solubilized
and purified G188R and P23H opsins [12]. CD spectroscopy
revealed that the purified mutant opsins had a 25% reduction in
a-helical content compared to properly folded purified opsin
[12]. The partial reduction in a-helical content indicates that the
misfolded mutants only partially misfold and retain the majority
of native secondary structure. Since FTIR spectroscopy is better sui-
ted at detecting b-sheet structure compared to CD spectroscopy
and can also be used to determine a-helical content [39], changes
in both a-helical and b-sheet structure were observed in the cur-
rent study whereas only changes in a-helical structure were
detectable by CD spectroscopy. The G188R and P23H mutations
appear to cause localized perturbations where b-sheet structure
is formed at least in part by conversion from native a-helical struc-
ture. Future FTIR studies on purified receptors will be required to
quantitatively assess changes in misfolded mutant opsin secondary
structure and to exclude secondary effects occurring in the ER that
may contribute to the FTIR spectrum obtained from a cell.
3.4. Implications of elevated b-sheet structure in opsin mutants
Aggregation of misfolded opsin mutants is not a result of non-
specific interactions of hydrophobic proteins, but rather, mediated
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Fig. 3. (A) Epifluorescence and (B) FTIR image of HEK293 cells expressing G188R opsin tagged with YFP. The FTIR image represents the relative b-sheet content at each pixel
as calculated by the b-sheet/amide I ratio. High levels of b-sheet content (red) overlap with regions of high YFP fluorescence. Scale bar, 20 lm. (C)–(H) FTIR and second
derivative spectra in the amide I region. (C) an (D) Spectra obtained from untransfected cells and cells expressing YFP-tagged WT opsin, untagged WT opsin, or YFP alone. (E)
and (F) Spectra obtained from cells expressing YFP-tagged WT, G188R, P23H, or WT-KKYL opsin. (G) and (H) Spectra obtained from cells expressing untagged WT, G188R, or
P23H opsin. Full spectra are shown in Supplemental Figs. S1–S3.
3124 L.M. Miller et al. / FEBS Letters 589 (2015) 3119–3125by specific interactions [41]. The detection of elevated b-sheet
structure in opsin mutants may provide a clue to how this speci-
ficity is achieved. Increased b-sheet structure is characteristic of
a wide range of peptides and globular proteins that form amyloids,
which are toxic to cells and cause a variety of diseases including
progressive neurodegenerative conditions such as Alzheimer’s dis-
ease, Huntington’s disease, Parkinson’s disease, and amyotrophic
lateral sclerosis [9,10]. b-Sheets mediate the interactions between
monomeric peptides or misfolded globular proteins to form amy-
loid oligomers or fibrils. Similar to amyloid-forming proteins, opsin
mutants display increased b-sheet structure and aggregation. Thus,
the specificity of misfolded mutant opsin aggregates may be
achieved by defined binding interfaces involving b-sheets. The
structures of misfolded opsin mutant aggregates are likely distinct
from those of amyloids, however, since staining is not observed by
thioflavin T or the anti-oligomer antibody A11 (data not shown),
which bind generic structures present in amyloid fibrils and oligo-
mers [42–44].
The similarities in effects observed for G188R and P23H opsins
suggest that all misfolded opsin mutants that cause RP may
undergo similar types of structural changes and aggregation. More-
over, misfolding of opsin promoted by environmental factors may
also cause similar structural transitions in the receptor as that
caused by mutation [40]. Findings from the current study may
have even broader implications. Rhodopsin is a prototypical mem-
ber of the G protein-coupled receptor (GPCR) family of cell surfacereceptors, one of the largest classes of proteins and therapeutic tar-
gets. Heritable mutations are also found in other GPCRs that cause
receptor misfolding, which results in disorders such as hypogo-
nadism, diabetes, and obesity [45]. The structure of these mis-
folded mutant GPCRs and their propensity to form aggregates is
unknown. Commonalities in the structure of GPCRs raise the pos-
sibility that increased b-sheet structure and specific aggregation
may be a common feature for all members of this family of proteins
that are prone to misfold when destabilizing mutations are
introduced.
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